Introduction

Adherence to anti-diabetic and antihypertensive medications is an area of interest with marked implications to affect patient management outcomes. The World Health Organization (WHO) defined adherence in 2001 as the extent to which a patient follows medical instructions [1]. Whereas this concept accounts for a broader aspect in the medical practice, its correlation with the management and control of chronic illnesses as diabetes and hypertension is well documented. This is likely because, adherence in this group encompasses multiple dimensions, such as lifestyle changes, medications, patient attitudes, and provider-patient relationships among others [2, 3] with potential interaction in the longer or lifetime frames.

Measuring adherence provides information on patients’ behavior to medication and lifestyle practices [4]. Studies have documented that the level of medication adherence in developed nations remained, only, close to 50% [5–7]. This figure is even lower in the developing and middle-income countries owed to the paucity of healthcare inputs and limited access to the services. Reports of adherence to antihypertensive medications from China (65.1%), Gambia (27%), and Seychelles (26%) showed the magnitude and relevance of the problem [8–10].

Medication adherence studies on antidiabetic and antihypertensive medications have been conducted across regions of Ethiopia. Even though the measurement tool and design of the study are similar for most of the studies, there is a considerable variation in terms of the level of adherence by study settings and type of chronic illness considered [11–14]. Reports from the present study setting also revealed that adherence levels to anti-diabetic medications ranged from 51.3% to 76% [15–17].

Currently, when the focus of pharmaceutical companies is on battling the COVID-19 pandemic across the globe, low and middle-income countries (LMICs) like Ethiopia, might be worst affected due to the rather vulnerable and inadequate pharmaceutical manufacturing capacities in these countries to meet their general pharmaceutical needs particularly those for chronic diseases. With limited supply to meet the increased demand created, the market values of medicines for chronic diseases have escalated, making them unaffordable for several patients in LMICs who require them [13]. Besides, adequate therapeutic outcomes of chronic illnesses require a linear adherence to medications [18]. This, in turn, could be linked to accessibility, affordability that can, negatively, be impacted during the outbreak [19].

Also, even though more studies have been conducted on the topic [11–17], potential variation in findings is inevitable due to time, study design, perception, context, the population considered, sample size, and quality of care delivered to patients among others. The purpose of this study is to assess the level of medication adherence, patients’ perception of the impact of the COVID-19 pandemic, and factors associated with poor adherence to anti-diabetic and antihypertensive medications among patients visiting public health facilities in Addis Ababa.

Methods

Results

Profile of patients

A total of 409 patients were included in the present study. Even though few patients declined to take part during the subsequent recruitment (n = 13), the number of respondents was beyond the minimum requirement. The age of patients ranged from 19 to 95 with a mean of 56.5 and a standard deviation (SD) of 13.4 Years. The majority were in the age group of 45 or above (321,78.5%), females (229,6%), visiting hospitals (224,54.8%), not attended formal education (174, 42.5%), married (259, 63.3%), live with moderate poverty or better (222, 54.3%), have comorbidity (250, 61.0%), with 7 years or less mean duration of disease (277, 67.7%) and 7 years or less mean duration of treatment (257, 62.8%). Most of the participants had no current history of any substance use (92.2%), diagnosed with hypertension only (35.0%), had no sleep disturbance (68.7%), have close people around (88.5%), and live with 3–5 family members (59.7%) (Table 1). Among the comorbidities reported, hypertension (204, 81.6%), diabetes mellitus (179, 71.6%), heart disease (66, 26.4%), hypercholesterolemia (36, 14.4%), chronic asthma (23, 9.2%), and stroke (12, 4.8%) accounted for the top frequencies. A Cronbach’s alpha test of the reliability of the scale among the samples also showed an acceptable range for both hospitals (α = 0.88) and health centers (α = 0.63).

Table 1

Profile of T2DM and hypertensive patients visiting chronic care units of public health facilities in Addis Ababa, August 2020.

Characteristic	Label	Frequency	%
Age (yrs.)
	≤45	88	21.5
	>45	321	78.5
Sex
	Male	180	44
	Female	229	56
Visiting site
	Health center	185	45.2
	Hospital	224	54.8
Education
	Not attended formal education	174	42.5
	Grades 1 to 12	165	40.4
	Diploma or above	70	17.1
Marital status
	Unmarried	53	13.0
	Married	259	63.3
	Divorced/separated/widowed	97	23.7
Income level (ETB) *
	Extreme poverty	187	45.7
	Moderate poverty or better	222	54.3
Presence of comorbidity
	No	159	38.9
	Yes	250	61.1
Disease duration**
	≤7 years	277	67.7
	>7 years	132	32.3
Treatment duration**
	≤7 years	257	62.8
	>7 years	152	37.2
Current substance use history
	Yes	32	7.8
	No	377	92.2
Diagnosis type
	Type 2 diabetes mellitus	132	32.2
	Hypertension	143	35.0
	Both T2DM and hypertension	134	32.8
Presence of sleep disturbance
	Yes	128	31.3
	No	281	68.7
Presence of close people
	No	47	11.5
	Yes	362	88.5
Number of family members
	≤2	79	19.3
	3–5	244	59.7
	≥6	86	21.0

*classified considered based on the World Bank’s definition of poverty [27].

** considered based on the mean duration (Yrs.) of diagnosis or initiation of treatment.

Patients’ perception of the impact of COVID-19 pandemic

About 163(40%) of the patients reported that the COVID-19 pandemic has posed negative impacts on the availability of medications and their follow-up visits, whereas 160(39%) believed that it caused an unaffordable or increased price of medications. Two hundred thirty-four (57%) reported that they have faced one or more of the problems whilst 87(21%) stated that they come across all the three (Fig 1).

Fig 1

Perception of T2DM and hypertensive patients on the impact of the COVID-19 pandemic visiting chronic care units of public facilities in Addis Ababa, August 2020.

Level of adherence to antidiabetic and antihypertensive medications

The level of adherence to antidiabetic and antihypertensive medications was measured using the 8-item Morisky medication adherence scale. Accordingly, the overall level of adherence was found to be 28% whilst 72% were poorly adherent missing at least one element from the scale (Fig 2).

Fig 2

Adherence level to antidiabetic and antihypertensive medications among patients visiting public health facilities during the COVID-19 pandemic in Addis Ababa, Ethiopia, August 2020.

Factors associated with poor medication adherence

Lastly, multiple characteristics of patients were tested against the presence of any potential association with poor medication adherence. Patients under extreme poverty were more likely to report a good adherence as compared to patients with moderate poverty or better average monthly income (AOR: 0.59; 95%C.I: 0.36–0.97). On the other hand, patients attending health centers (AOR: 1.71; 95%C.I: 1.02–2.85), having any comorbidity (AOR: 2.05; 95%C.I: 1.13–3.71), and current history of any substance use (AOR: 11.57; 95%C.I: 1.52–88.05) have shown a statistically significant positive association with poor medication adherence (Table 2).

Table 2

Factors associated with poor adherence to antidiabetic and antihypertensive medications among patients visiting public health facilities during the COVID-19 pandemic in Addis Ababa, Ethiopia, August 2020.

Variable	Label	Level of adherence		COR (95%CI)	AOR (95%CI)
		Good (n)	Poor (n)
Facility level
	Health centers	38	147	1.98(1.27–3.12)	1.71(1.02–2.85)*
	Hospitals	76	148	1	1
Education
	Not attended formal education	35	139	1.94(1.04–3.62)	1.85(0.94–3.63)
	Primary/secondary education	56	109	0.95(0.53–1.73)	0.96(0.50–1.84)
	College/University education	23	47	1	1
Average monthly income (ETB) d
	Extreme poverty	58	129	0.75(0.49–1.16)	0.50(0.27–0.89)*
	Moderate poverty or better	56	166	1	1
Comorbid condition
	No	56	103	1	1
	Yes	58	192	0.56(0.36–0.86)	2.05(1.13–3.71)*
Current history of substance use
	Yes	1	31	13.27(1.79–98.39)	11.44(1.50–87.11)*
	No	113	264	1	1
Diagnosis type
	T2DM	42	90	0.59(0.34–1.03)	1.06(0.52–2.16)
	Hypertension	43	100	0.64(0.37–1.11)	0.92(0.48–1.77)
	Both T2DM and hypertension	29	105	1	1
Presence of sleep disturbance
	Yes	28	100	1.58(0.97–2.57)	1.44(0.86–2.42)
	No	86	195	1	1
Presence of close people around
	No	7	40	2.40(1.04–5.52)	2.03(0.84–4.90)
	Yes	107	255	1	1

*indicates statistical significance at P≤0.05. COR: crude odds ratio; AOR: adjusted odds ratio.

Discussion

The COVID-19 pandemic has severely affected health systems in general and follow-up service to chronic illnesses in particular [28–30]. Its impact in Sub-Saharan Africa is more pronounced as this region is often characterized by low health system infrastructure coupled with a growing burden of non-communicable diseases [31]. In Ethiopia too, most healthcare services have been disrupted due to the alarming spread of the pandemic and daily loaded terrifying news [32]. Augmented with less attention of the public to regularly practice preventive measures, more patients are still at risk of either its direct or indirect impacts militating their adherence to therapy. It is apparent from the present study that the majority of patients experienced negative impacts on either of their follow-visits, availability, or affordability of medications at least once during the outbreak. It was also noted that about a fifth of the patients in the present sample reported having faced all of the problems.

Evaluation of adherence to medication level could be regarded as a potential indicator for patients’ commitment to reverse an affected state of health [33]. Poor adherence to long-term medications is multifactorial often comprising socio-demographic factors, individual patient-related, therapy-related factors, and the health system among others [34]. As a result, achieving proper adherence remains to be a challenge both in the developed [5, 6] and developing [7–10] countries even though pharmacotherapy remains to be the mainstay of treatment especially among the older population [35].

The present study shows that level of poor adherence, where a patient failed to meet all the recommended criteria, was found to be significantly high (72%). This figure is higher as compared to the level of adherence to antihypertensive medications reported from Southwest Ethiopia (61.8%) by Asgedom and his colleagues [11], in Hawassa (67%) documented by Getnet et al. [12], and in Addis Ababa (66.7%) reported by Tibebu and his colleagues [13]. The highest level of adherence (75%) to antihypertensive medications was reported from Northwest Ethiopia as well [14]. More precisely, the earlier studies have indicated that at least half a proportion of the patients in Addis Ababa had a good level of adherence to their antihypertensive [13] and antidiabetic medications [15–17]. Whereas multiple contributors would result in a poor outcome, the impact of the COVID-19 pandemic six months before the study period was undeniably notable [32, 36]. Most patients have also implied in their report of perceived negative influence the outbreak had posed in terms of meeting with follow-up appointments, accessing medicines, and affording for prices. These factors are mentioned to account for a remarkable role in patients’ poor adherence to therapy [37, 38].

Studies documented that various factors have a link with poor adherence to medications among patients with chronic illness. These may include; lack of involvement of family and friends [39], economic difficulties [40], poor relationship between professional and patients [41], and side effects as well as the complexity of regimens [41, 42]. Furthermore, while patients with asymptomatic diseases have less incentive to adhere to medications, the presence of multiple comorbid conditions that are treated with more drugs can also impair attaining proper adherence [34, 43, 44]. The earlier studies done in Ethiopia have indicated that such contributors, as comorbidity [11–13], age group [12–14], level of knowledge about disease and medication [12–14, 16], and level of education [15, 16] were reported to be among the factors associated with medication adherence.

In paradox with the popular belief [40, 45], lower-income was found to be associated with higher odds of good adherence to anti-diabetic and antihypertensive medications in the current setting. Though the connection of income and health is well established in terms of either direct effect on material fulfillment or indirectly through ensuring social participation [46], the present association could be confounded with non-income factors. In the current Ethiopian context, all patients under the poverty line (45.7% of the respondents) are waived insurance fees that may improve their service utilization rate and access to medicines. Yet, adherence is a behavior of composite factors [34] that can be altered even apart from gaining access to service and medications. Taking into account non-compliance consequences, poor patients might tend to apply medical advice or maintain good relations with providers.

On the other hand, attending a health center, having any comorbid condition and current history of any substance use have shown a statistically significant positive association with poor medication adherence. An increase in the odds of poor adherence among patients attending health centers would be related to patients’ health-seeking behavior, the severity of complications, patient loads, or perceived poor availability of COVID-19 preventive measures at these settings. That could be likely because, as primary healthcare units in the Ethiopian health system, health centers serve to catchment populations that do not need advanced diagnosis and treatment. This is in line with other studies that reported that having a comorbid condition [11] and substance use history [11, 47] were associated with high odds of poor medication adherence. This could also be attributed to the fact that patients may either not be able to comprehend the outcome of their disease and benefit of adherence to medications [48], experience side effects of polypharmacy [49] or fail to practice a healthy lifestyle.

This study has tried to present a city-wide comprehensive report on the medication adherence practice of patients visiting public health facilities in Addis Ababa, Ethiopia. Apart from being able to include various strata of facilities and patients, the findings can be easily compared to previous figures to evaluate the impact imposed by the COVID-19 pandemic on medication adherence. However, the observed association between dependent and independent variables may suffer from temporality. Inclusion of the only patients who were available during the study period could also pose a selection bias that might have affected the study results.

Conclusion

A significant proportion of patients with T2DM and hypertension in Addis Ababa have experienced negative impacts on either of their follow-visits, availability, or affordability of medications at least once during the COVID-19 outbreak. Over a three-fourth of the patients had poor adherence to their medications. Facility type, average monthly income, level of education, presence of comorbidity, and current histories of any substance use have shown a statistically significant association with poor adherence to antidiabetic and antihypertensive medications.

All concerned health authorities should take into account, and set multidisciplinary strategies to prevent impacts of the COVID-19 pandemic on medication adherence of patients with chronic illnesses.